bluebird bio Statistics
Total Valuation
Evolus has a market cap or net worth of $421.10 million. The enterprise value is $514.27 million.
Important Dates
The last earnings date was Tuesday, August 5, 2025, after market close.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolus has 64.69 million shares outstanding. The number of shares has increased by 8.05% in one year.
| Current Share Class | 64.69M |
| Shares Outstanding | 64.69M |
| Shares Change (YoY) | +8.05% |
| Shares Change (QoQ) | +1.32% |
| Owned by Insiders (%) | 1.92% |
| Owned by Institutions (%) | 72.19% |
| Float | 54.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.49 |
| Forward PS | 1.58 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.27
| Current Ratio | 2.27 |
| Quick Ratio | 1.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.95 |
Financial Efficiency
Return on equity (ROE) is -18,729.61% and return on invested capital (ROIC) is -18.13%.
| Return on Equity (ROE) | -18,729.61% |
| Return on Assets (ROA) | -11.06% |
| Return on Invested Capital (ROIC) | -18.13% |
| Return on Capital Employed (ROCE) | -24.80% |
| Revenue Per Employee | $837,172 |
| Profits Per Employee | -$186,732 |
| Employee Count | 332 |
| Asset Turnover | 1.20 |
| Inventory Turnover | 4.58 |
Taxes
In the past 12 months, Evolus has paid $699,000 in taxes.
| Income Tax | 699,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.11% in the last 52 weeks. The beta is 1.12, so Evolus's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | -50.11% |
| 50-Day Moving Average | 9.05 |
| 200-Day Moving Average | 11.53 |
| Relative Strength Index (RSI) | 28.89 |
| Average Volume (20 Days) | 2,230,371 |
Short Selling Information
The latest short interest is 13.48 million, so 20.84% of the outstanding shares have been sold short.
| Short Interest | 13.48M |
| Short Previous Month | 12.63M |
| Short % of Shares Out | 20.84% |
| Short % of Float | 24.72% |
| Short Ratio (days to cover) | 14.62 |
Income Statement
In the last 12 months, Evolus had revenue of $277.94 million and -$62.00 million in losses. Loss per share was -$0.97.
| Revenue | 277.94M |
| Gross Profit | 186.71M |
| Operating Income | -40.94M |
| Pretax Income | -52.99M |
| Net Income | -62.00M |
| EBITDA | -35.18M |
| EBIT | -40.94M |
| Loss Per Share | -$0.97 |
Full Income StatementBalance Sheet
The company has $61.74 million in cash and $154.91 million in debt, giving a net cash position of -$93.17 million or -$1.44 per share.
| Cash & Cash Equivalents | 61.74M |
| Total Debt | 154.91M |
| Net Cash | -93.17M |
| Net Cash Per Share | -$1.44 |
| Equity (Book Value) | -18.65M |
| Book Value Per Share | -0.29 |
| Working Capital | 81.22M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$41.34 million and capital expenditures -$1.76 million, giving a free cash flow of -$43.10 million.
| Operating Cash Flow | -41.34M |
| Capital Expenditures | -1.76M |
| Free Cash Flow | -43.10M |
| FCF Per Share | -$0.67 |
Full Cash Flow StatementMargins
Gross margin is 67.18%, with operating and profit margins of -14.73% and -22.31%.
| Gross Margin | 67.18% |
| Operating Margin | -14.73% |
| Pretax Margin | -22.05% |
| Profit Margin | -22.31% |
| EBITDA Margin | -12.66% |
| EBIT Margin | -14.73% |
| FCF Margin | n/a |
Dividends & Yields
Evolus does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.05% |
| Shareholder Yield | -8.05% |
| Earnings Yield | -14.72% |
| FCF Yield | -10.23% |
Analyst Forecast
The average price target for Evolus is $21.25, which is 226.42% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.25 |
| Price Target Difference | 226.42% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 25.77% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolus has an Altman Z-Score of -0.92 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.92 |
| Piotroski F-Score | 2 |
